Irbesartan+hidroclorotiazida Fisiofen (Hydrochlorothiazide, Irbesartan)

Irbesartan blocks the AT1 receptors for angiotensin II, preventing vasoconstriction and aldosterone release. This leads to relaxation of blood vessels and a reduction in peripheral resistance, contributing to lower blood pressure.

The appropriate dose is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and other individual factors. Patients should follow the exact dosage instructions provided by their healthcare professional.

Safety in pregnancy and lactation has not been established for this combination. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and only under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Irbesartan+hidroclorotiazida combines a selective AT1‑receptor blocker with a thiazide diuretic, offering dual mechanisms that can be more effective than monotherapy for some patients. Compared with ACE inhibitors or calcium‑channel blockers, it may provide better blood‑pressure control with a different side‑effect profile, but choice depends on individual patient factors.

Store the tablets at ambient temperature, below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight, and excessive heat to maintain product stability.

The medication is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe dehydration, electrolyte imbalances (especially low potassium), acute kidney injury, significant hypotension, and rare allergic reactions such as angioedema. Patients should report symptoms like faintness, rapid weight loss, swelling, or rash to their clinician promptly.

The combination should be avoided in patients with known hypersensitivity to irbesartan, hydrochlorothiazide, or any component of the formulation. It is also contraindicated in individuals with severe renal impairment, anuria, or those who are pregnant unless the benefits outweigh the risks.